Taysha Gene Therapies, a biotech company developing gene therapies for severe CNS diseases, will release its Q2 2026 financial results on August 11, 2026. The company will also hold a conference call and webcast to provide updates on its progress, including its lead program TSHA-102 for Rett syndrome. This event offers investors insight into the company’s development pipeline and strategic direction. An archived replay will be available on Taysha’s website after the live event.
Oil prices fell on Monday as traders monitored the steady flow of Middle East oil despite recent attacks on Saudi Arabia's East-West pipeline by Iran-backed Houthis. Brent crude dropped 1.66% to $102.15 per barrel, and US West Texas Intermediate fell...
CashCat's price fell about 30% in 24 hours due to broader crypto market weakness, breaking a key resistance but reaching a support level within a bullish channel. Indicators show bears currently dominate, yet rising Money Flow Index and positive Fund...
Solidion Technology has combined the roles of Chairman and CEO, appointing Jaymes Winters to lead both positions to strengthen governance and strategic execution. Winters brings over 15 years of CEO experience across various industries and will focus...
FireFly Metals is closing its A$10 million share purchase plan (SPP) on September 23, following a successful A$180 million equity raise earlier this month. The funding supports development of the Green Bay Copper-Gold Project in Newfoundland, includi...
Ethereum's euro-denominated stablecoin market cap grew by $32 million in the past 30 days, making up most of a $39.9 million increase across three networks. This growth highlights Ethereum's dominance with a 69.5% market share in a sector that expand...
